# EDGAR Filing Document

**Accession Number:** 0001492422
**File Stem:** 0001127602-23-001002
**Filing Date:** 2023-1
**Character Count:** 7924
**Document Hash:** 902b984165b5aec1ac92e95fc9d060bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001127602-23-001002.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001127602-23-001002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230103

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Baumal Caroline
- **CENTRAL INDEX KEY:** 0001961100

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38276
- **FILM NUMBER:** 23513211

**MAIL ADDRESS:**
- **STREET 1:** C/O APELLIS PHARMACEUTICALS, INC.
- **STREET 2:** 100 5TH AVENUE, 3RD FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apellis Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001492422
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 271537290
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 FIFTH AVENUE
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 617-977-5700

**MAIL ADDRESS:**
- **STREET 1:** 100 FIFTH AVENUE
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

## Ex-24

```

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes
 and appoints each of David Watson and Timothy Sullivan, signing singly
and each acting individually, as the undersigned?s true and lawful
attorneyinfact with full power and authority as hereinafter described to
1	execute for and on behalf of the undersigned, in the undersigned?s
capacity as an officer and/or director of Apellis Pharmaceuticals, Inc.
the Company, Forms 3, 4, and 5 including any amendments thereto in
accordance with Section 16a of the Securities Exchange Act of 1934 and
the rules thereunder the Exchange Act
2	do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to prepare, complete and execute any
such Form 3, 4, or 5, prepare, complete and execute any amendment or
amendments thereto, and timely deliver and file such form with the United
States Securities and Exchange Commission and any stock exchange or
similar authority
3	seek or obtain, as the undersigned?s representative and on the
undersigned?s behalf, information regarding transactions in the Company?s
securities from any third party, including brokers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
person to release any such information to such attorneyinfact and approves
and ratifies any such release of information and
4	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorneyinfact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorneyinfact on
behalf of the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorneyinfact may approve in such attorneyinfact?s discretion.
The undersigned hereby grants to each such attorneyinfact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes
as the undersigned might or could do if personally present, with full power
of substitution or revocation, hereby ratifying and confirming all that
such attorneyinfact, or such attorneyinfact?s substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneysinfact, in serving in such capacity at the
request of the undersigned, are not assuming nor relieving, nor is the
Company assuming nor relieving, any of the undersigned?s responsibilities
to comply with Section 16 of the Exchange Act. The undersigned acknowledges
 that neither the Company nor the foregoing attorneysinfact assume i
any liability for the undersigned?s responsibility to comply with the
requirement of the Exchange Act, ii any liability of the undersigned for
any failure to comply with such requirements, or iii any obligation or
liability of the undersigned for profit disgorgement under Section 16b
of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect
to the undersigned?s holdings of and transactions in securities issued by
the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneysinfact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this  3	 day of January, 2023.

Signature

 Caroline Baumal	 Print Name

ActiveUS 179092563v.2

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Baumal Caroline<br><sub>(Last) (First) (Middle)</sub><br>100 5TH AVENUE<br><sub>(Street)</sub><br>WALTHAM, MA 02451<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Apellis Pharmaceuticals, Inc. [ APLS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-03 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 133.37 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Signature:** /s/ David Watson, attorney-in-fact for Caroline Baumal  
**Date:** 2023-01-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**